Exelon Approved For Parkinson’s Dementia
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved Novartis' Exelon (rivastigmine) June 27 for treatment of mild to moderate dementia related to Parkinson's disease
You may also be interested in...
Novartis To Submit Exelon Patch By Year-End
Novartis plans to submit a transdermal patch formulation of its Alzheimer's disease therapy Exelon (rivastigmine) by year-end, the firm said July 19
Novartis To Submit Exelon Patch By Year-End
Novartis plans to submit a transdermal patch formulation of its Alzheimer's disease therapy Exelon (rivastigmine) by year-end, the firm said July 19
Exelon sNDA For Parkinson’s-Related Dementia Requires Just One Trial, Committee Says
FDA’s Peripheral & Central Nervous Systems Drugs Advisory Committee agrees that dementia associated with Parkinson’s disease qualifies as distinct from Alzheimer’s-type dementia.